RNAi inhibition of alpha-ENaC expression

Details for Australian Patent Application No. 2008263876 (hide)

Owner Novartis AG

Inventors Vornlocher, Hans-Peter; Hickman, Emma; Geick, Anke; Danahay, Henry Luke; Tan, Pamela; Van Heeke, Gino

Agent Davies Collison Cave

Pub. Number AU-B-2008263876

PCT Pub. Number WO2008/152131

Priority 07110376.6 15.06.07 EP; 07114265.7 13.08.07 EP

Filing date 13 June 2008

Wipo publication date 18 December 2008

Acceptance publication date 12 April 2012

International Classifications

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

C07H 21/00 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

24 December 2009 PCT application entered the National Phase

  PCT publication WO2008/152131 Priority application(s): WO2008/152131

12 April 2012 Application Accepted

  Published as AU-B-2008263876

9 August 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008263878-Access domain selection in a communications network

2008263866-Method for treating an at least partially metallised textile, treated textile and use thereof